61. Desai S, Rashmi S, Rane A, Dharavath B, Sawant A, Dutt A. An integrated approach to determine the abundance, mutation rate and phylogeny of the SARS-CoV-2 genome. Brief Bioinform. 2021 Mar 22;22(2):1065-1075. doi: 10.1093/bib/bbaa437. PMID: 33479725, PMCID: PMC7929363
[READ] [SUMMARY]
   
62. Joshi A, Mishra R, Desai S, Chandrani P, Kore H, Sunder R, Hait S, Iyer P, Trivedi V, Choughule A, Noronha V, Joshi A, Patil V, Menon N, Kumar R, Prabhash K, Dutt A. Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations. Oncotarget. 2021 Mar 16;12(6):578-588. doi: 10.18632/oncotarget.27905. eCollection 2021 Mar 16. PMID: 33796225, PMCID: PMC7984830
[READ] [SUMMARY]
   
63. Desai S, Rane A, Joshi A,Dutt A. IPD 2.0: To derive insights from an evolving SARS-CoV-2 genome. BMC Bioinformatics. 2021 May 13;22(1):247. doi:10.1186/s12859-021-04172-x. PMID: 33985433, PMCID: PMC8118100
[READ] [SUMMARY]
   
64. Butle A, Joshi A, Noronha V, Prabhash K,Dutt A. Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs.Transl Oncol. 2021 Aug;14(8):101111. doi: 10.1016/j.tranon.2021.101111. Epub 2021 May 13. PMID: 33993094, PMCID: PMC8236545
[READ] [SUMMARY]
   
65. Desai S, Dharavath B, Manavalan S, Rane A, Redhu AK, Sunder R, Butle A, Mishra R, Joshi A, Togar T, Apte S, Bala P, Chandrani P, Chopra S, Bashyam MD, Banerjee A, Prabhash K, Nair S,Dutt A. Fusobacterium nucleatum is associated with inflammation and poor survival in early-stage HPV-negative tongue cancer. NAR Cancer 2022 Mar 4;4(1):zcac006. doi: 10.1093/narcan/zcac006. eCollection 2022 Mar. PMID: 35252868, PMCID: PMC8894079
[READ] [SUMMARY]
   
66. Desai S, Mishra R, Ahmad S, Hait S, Joshi A, Dutt A. TMC-SNPdb 2.0: an ethnic-specific database of Indian germline variants. Database (Oxford) 2022, May 11;2022. pii: baac029. doi: 10.1093/database/baac029. PMID:35551364, PMCID: PMC9216475
[READ] [SUMMARY]
   
67. Joshi A, Butle A, Hait S, Mishra R, Trivedi V, Thorat R, Choughule A, Noronha V, Prabhash K Dutt A. Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation. Transl Oncol. 2022 Aug;22:101461. doi: 10.1016/j.tranon.2022.101461. Epub 2022 May 30. PMID: 35653897, PMCID: PMC9156817
[READ] [SUMMARY]
   
68. Yadav N, Sunder R, Desai S, Dharavath B, Chandrani P, Godbole M, Dutt A. Progesterone modulates the DSCAM-AS1/miR-130a/ESR1 axis to suppress cell invasion and migration in breast cancer. Breast Cancer Res. 2022, Dec 28;24(1):97. doi: 10.1186/s13058-022-01597-x. PMID: 36578092, PMCID: PMC9798554
[READ] [SUMMARY]
   
69. Noronha V, Chougule A, Chandrani P, Kaushal RK, Patil VM, Menon N, Kapoor A, Chopade S, Singh A, Shetty O, Banavali S, Prabhash K. Dutt A. Lung cancer with dual EGFR and ALK driver alterations at baseline: a retrospective observational cohort study. Acta Oncol. 2022, Sep;61(9):1143-1147. doi: 10.1080/0284186X.2022.2109426. Epub 2022 Aug 16. PMID: 35972844
[READ]
   
70. Rekhi B, Dodd L, Dharavath B, Dutt A. Cytomorphology of spindle cell/sclerosing rhabdomyosarcoma, including MYOD1 (LI22R) mutation result. Diagn Cytopathol. 2022, Dec;50(12):E367-E372. doi: 10.1002/dc.25032. Epub 2022 Aug 5. PMID: 35929754
[READ]
   
71. Behel V, Noronha V, Choughule A, Shetty O, Chandrani P, Kapoor A, Bondili SK, Bajpai J, Kumar R, Pai T, Bal M, Gurav M, Bapat P, Mittal N, Menon S, Patil V, Menon N, Prabhash KDutt A. Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer. JCO Glob Oncol. 2022, Jul;8:e2200030. doi: 10.1200/GO.22.00030.PMID: 35802838 PMCID: PMC9296182
[READ]